As of 2024-12-12, the EV/EBITDA ratio of SAGE Therapeutics Inc (SAGE) is -0.70. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SAGE's latest enterprise value is 260.66 mil USD. SAGE's TTM EBITDA according to its financial statements is -371.26 mil USD. Dividing these 2 quantities gives us the above SAGE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.0x - 15.2x | 13.9x |
| Forward P/E multiples | 15.7x - 21.4x | 15.8x |
| Fair Price | (93.90) - (90.38) | (88.50) |
| Upside | -1694.2% - -1634.5% | -1602.5% |
| Date | EV/EBITDA |
| 2024-12-11 | -0.70 |
| 2024-12-10 | -0.65 |
| 2024-12-09 | -0.65 |
| 2024-12-06 | -0.66 |
| 2024-12-05 | -0.65 |
| 2024-12-04 | -0.66 |
| 2024-12-03 | -0.65 |
| 2024-12-02 | -0.69 |
| 2024-11-29 | -0.63 |
| 2024-11-27 | -0.65 |
| 2024-11-26 | -0.68 |
| 2024-11-25 | -0.60 |
| 2024-11-22 | -0.58 |
| 2024-11-21 | -0.53 |
| 2024-11-20 | -0.54 |
| 2024-11-19 | -0.54 |
| 2024-11-18 | -0.52 |
| 2024-11-15 | -0.57 |
| 2024-11-14 | -0.62 |
| 2024-11-13 | -0.68 |
| 2024-11-12 | -0.68 |
| 2024-11-11 | -0.77 |
| 2024-11-08 | -0.77 |
| 2024-11-07 | -0.77 |
| 2024-11-06 | -0.71 |
| 2024-11-05 | -0.71 |
| 2024-11-04 | -0.69 |
| 2024-11-01 | -0.73 |
| 2024-10-31 | -0.73 |
| 2024-10-30 | -0.79 |
| 2024-10-29 | -1.13 |
| 2024-10-28 | -1.14 |
| 2024-10-25 | -1.05 |
| 2024-10-24 | -1.03 |
| 2024-10-23 | -0.99 |
| 2024-10-22 | -0.99 |
| 2024-10-21 | -1.02 |
| 2024-10-18 | -0.98 |
| 2024-10-17 | -0.92 |
| 2024-10-16 | -0.93 |
| 2024-10-15 | -0.86 |
| 2024-10-14 | -0.85 |
| 2024-10-11 | -0.82 |
| 2024-10-10 | -0.78 |
| 2024-10-09 | -0.80 |
| 2024-10-08 | -0.79 |
| 2024-10-07 | -0.84 |
| 2024-10-04 | -0.83 |
| 2024-10-03 | -0.88 |
| 2024-10-02 | -0.88 |